Gain Certainty in
Breast Cancer Treatment
With actionable results using an accurate predictive1,2 and prognostic2-8 test with LoE1A in ESMO Guidelines9
How to Predict Recurrence of Early-Stage Breast Cancer
A comprehensive tool for breast cancer treatment decisions
Genomic testing for breast cancer recurrence is guiding critical treatment decision making in early‑stage breast cancer. It helps clinicians to personalize treatment and avoid unnecessary side effects, ensuring each woman receives the therapy that’s right for her.
EndoPredict is a genomic test that accurately predicts the risk of recurrence in early-stage ER-positive, HER2-negative (ER+/HER2–) breast cancer – up to 15 years after diagnosis.1,2 It also indicates whether a patient is likely to benefit from chemotherapy,3,4 helping guide truly personalized treatment decisions.
EndoPredict® Uses Molecular Biology and Clinical Pathological Factors to Help Answer Critical Treatment Questions
By combining three key factors – a molecular score, tumor size, and nodal status – EndoPredict provides more prognostic information than first-generation tests that assess gene expression alone.1,5
EndoPredict includes genes specifically validated to predict both early and late distant recurrence10 in ER+/HER2– breast cancer, offering valuable guidance for long-term treatment planning.
Here are the three key questions EndoPredict helps answer:
Might adjuvant chemotherapy be needed?
EndoPredict is a highly accurate prognostic test to guide early treatment decisions, providing an individual risk of ER+/HER2- breast cancer recurrence at 10 years – critical information to determine whether chemotherapy is truly necessary.1,5,6
Might chemotherapy provide benefit?
Some women will benefit more from chemotherapy than others – EndoPredict provides the personalized chemobenefit for every patient with ER+/HER2- early-stage breast cancer to guide decision making.3,4
Might extended endocrine therapy be needed?
EndoPredict is one of the few tests clinically validated to predict ER+/HER2- breast cancer late recurrence risk (year 5-15), helping clinicians decide if extended endocrine therapy is needed.2
Learn more
A More Accurate Decision-Making Tool for Breast Cancer Treatment Decisions5,6
How does EndoPredict® compare to other genomic tests?
Not all breast cancer tests provide the same insights. Differences in clinical validation, long-term risk prediction, and guidance for chemotherapy decisions can significantly impact patient care. EndoPredict stands out with reliable evidence, including long-term follow-up data and proven chemotherapy benefit prediction in ER+/HER2- early-stage breast cancer.1-8 Compare leading genomic tests to understand what sets EndoPredict apart – and why test selection is critical for optimized patient care.
Watch the ESMO Industry Satellite Symposium
Watch the ESMO Satellite Symposium recordings to discover how genomic testing is transforming breast cancer treatment decisions. Chaired by Prof. Pascal Pujol and Prof. Carsten Denkert, the sessions feature prospective real-world data, user experience, and patient cases – highlighting the predictive and prognostic power of EndoPredict.
Eurobio Scientific
EndoPredict®
How can the EndoPredict® test help you?
Clinicians
Support your treatment decisions with a trusted, evidence-based tool. Discover how EndoPredict can enhance risk stratification and guide personalized care strategies.
Pathologists & Labs
Precision starts in the lab. Explore EndoPredict, designed for high reliability, reproducibility, and seamless integration into your workflow.
Patients
Understanding your options is the first step toward confident decisions. Learn how EndoPredict can help personalize your treatment and give you greater peace of mind.
EndoPredict® Testing – Fast, Local, Reliable
The EndoPredict breast cancer prognostic and chemotherapy predictive test is a CE-marked in vitro diagnostic (IVD) test.
It can be performed in local molecular pathology laboratories. The results are available within a few days and the test cost refund is assured for eligible patients in many countries.
Fast turnaround time
Endorsed by international guidelines
Available from local labs
How to Access EndoPredict®
Order EndoPredict
Local Testing with EndoPredict
References
- Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011; 17(18):6012-6020
- Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019;25:3865-3872
- Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019; 176:377-386
- Klein, E. et al.: Long-term outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer. Breast Cancer Res Treat. 2024; 207, 119-127
- Buus R. et al.: Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
- Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018
- Constantinidou A. et al.: Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. Clin. Cancer Res. 2022
- Sestak I. et al.: Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer. Clin Cancer Res. 2020
- Loibl S. et al.: Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023
- Dubsky, Peter et al. “The Endopredict Score Provides Prognostic Information On Late Distant Metastases In ER+/HER2− Breast Cancer Patients“. British Journal Of Cancer, vol 109, no. 12, 2013
